Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alice Long

Showing results (1-10 of 90) with videos related to

Pageof 9
Sort By:
The Lancet. Diabetes & Endocrinology|March 4, 2021
Combination therapy in recent-onset type 1 diabetesS Alice Long, Cate Speake
Current Opinion in Endocrinology, Diabetes, and Obesity|June 29, 2013
Intersection between genetic polymorphisms and immune deviation in type 1 diabetesAlice Long, Jane H Buckner
Journal of Immunology (Baltimore, Md. : 1950)|August 23, 2011
CD4+FOXP3+ T regulatory cells in human autoimmunity: more than a numbers gameS Alice Long, Jane H Buckner
Clinical and Experimental Immunology|August 18, 2022
Clinical and experimental treatment of type 1 diabetesS Alice Long, Jane H Buckner
Cold Spring Harbor Perspectives in Medicine|May 21, 2024
Integrating Omics into Functional Biomarkers of Type 1 DiabetesS Alice Long, Peter S Linsley
Journal of Autoimmunity|March 4, 2008
Combination of rapamycin and IL-2 increases de novo induction of human CD4(+)CD25(+)FOXP3(+) T cellsS Alice Long, Jane H Buckner
Current Opinion in Endocrinology, Diabetes, and Obesity|June 4, 2019
Enforcing the checkpoints: harnessing T-cell exhaustion for therapy of T1DPeter S Linsley, S Alice Long
Clinical Immunology (Orlando, Fla.)|March 1, 2014
Renegade homeostatic cytokine responses in T1D: drivers of regulatory/effector T cell imbalanceShipra Gupta, Karen Cerosaletti, S Alice Long
Immunology and Cell Biology|January 23, 2021
The many faces of islet antigen-specific CD8 T cells: clues to clinical outcome in type 1 diabetesAlice E Wiedeman, Cate Speake, Sarah Alice Long
Clinical Immunology (Orlando, Fla.)|March 19, 2013
IL-2 therapy in type 1 diabetes: "Trials" and tribulationsS Alice Long, Jane H Buckner, Carla J Greenbaum
Pageof 9

Showing results (1-10 of 90) with videos related to

Sort By:
Pageof 9
The Lancet. Diabetes & Endocrinology|March 4, 2021
Combination therapy in recent-onset type 1 diabetesS Alice Long, Cate Speake
Current Opinion in Endocrinology, Diabetes, and Obesity|June 29, 2013
Intersection between genetic polymorphisms and immune deviation in type 1 diabetesAlice Long, Jane H Buckner
Journal of Immunology (Baltimore, Md. : 1950)|August 23, 2011
CD4+FOXP3+ T regulatory cells in human autoimmunity: more than a numbers gameS Alice Long, Jane H Buckner
Clinical and Experimental Immunology|August 18, 2022
Clinical and experimental treatment of type 1 diabetesS Alice Long, Jane H Buckner
Cold Spring Harbor Perspectives in Medicine|May 21, 2024
Integrating Omics into Functional Biomarkers of Type 1 DiabetesS Alice Long, Peter S Linsley
Journal of Autoimmunity|March 4, 2008
Combination of rapamycin and IL-2 increases de novo induction of human CD4(+)CD25(+)FOXP3(+) T cellsS Alice Long, Jane H Buckner
Current Opinion in Endocrinology, Diabetes, and Obesity|June 4, 2019
Enforcing the checkpoints: harnessing T-cell exhaustion for therapy of T1DPeter S Linsley, S Alice Long
Clinical Immunology (Orlando, Fla.)|March 1, 2014
Renegade homeostatic cytokine responses in T1D: drivers of regulatory/effector T cell imbalanceShipra Gupta, Karen Cerosaletti, S Alice Long
Immunology and Cell Biology|January 23, 2021
The many faces of islet antigen-specific CD8 T cells: clues to clinical outcome in type 1 diabetesAlice E Wiedeman, Cate Speake, Sarah Alice Long
Clinical Immunology (Orlando, Fla.)|March 19, 2013
IL-2 therapy in type 1 diabetes: "Trials" and tribulationsS Alice Long, Jane H Buckner, Carla J Greenbaum
Pageof 9